BioCentury
ARTICLE | Clinical News

AC-201: Completed Phase IIb enrollment

September 12, 2011 7:00 AM UTC

TWi completed enrollment of 240 patients with Type II diabetes in a double-blind, placebo-controlled, U.S. and Taiwanese Phase IIb trial evaluating 25, 50 and 75 mg twice-daily AC-201 for 24 weeks. TW...